Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 1/2016

01-01-2016 | Clinical Investigation

Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation

Authors: Masaaki Saito, Tomohiro Iida, Mariko Kano, Kanako Itagaki

Published in: Japanese Journal of Ophthalmology | Issue 1/2016

Login to get access

Abstract

Purpose

The aim of this study was clarify the efficacy of combination therapy of intravitreal ranibizumab (IVR) injections and photodynamic therapy (PDT) in patients with symptomatic retinal angiomatous proliferation (RAP) over 24 months.

Methods

We retrospectively reviewed 37 naïve eyes of 31 patients treated with three consecutive monthly IVR injections (0.5 mg/0.05 ml) and PDT and followed for at least 24 months.

Results

The mean logarithm of the minimum angle of resolution best-corrected visual acuity levels improved significantly (P < 0.0001) from 0.63 at baseline to 0.39 at 24 months. Geographic atrophy (GA) involving the fovea developed in nine (24 %) eyes, with a significant (P = 0.036) decrease in VA at 24 months and a high (100 %) prevalence of reticular pseudodrusen (RPD) at baseline. Complete occlusion of the retinal–retinal anastomosis seen in 35 eyes was achieved in 33 eyes at month 24. The central retinal thickness decreased significantly (P < 0.0001) from 415 to 129 μm at 24 months. The mean number of treatments during 24 months was 2.5 PDT and 5.5 IVR injections.

Conclusions

Combination therapy comprising IVR injections and PDT is generally effective in maintaining or improving VA and retinal morphology within 2 years in eyes with RAP, except for eyes with baseline RPD, which are likely to develop GA in the fovea resulting in reduced VA.
Literature
1.
Yannuzzi LA, Negrão S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416–34.PubMedCrossRef
2.
Yannuzzi LA. Degeneration: age-related macular degeneration. In: The retinal atlas. Philadelphia: Saunders; 2010. p. 592–602.
3.
Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina. 2008;28:201–11.PubMedCrossRef
4.
Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.PubMedCrossRef
5.
Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology. 1996;103:2042–53.PubMedCrossRef
6.
Bottoni F, Massacesi A, Cigada M, Viola F, Musicco I, Staurenghi G. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol. 2005;123:1644–50.PubMedCrossRef
7.
Slakter JS, Yannuzzi LA, Schneider U, Sorenson JA, Ciardella A, Guyer DR, et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2000;107:742–53.PubMedCrossRef
8.
Kuroiwa S, Arai J, Gaun S, Iida T, Yoshimura N. Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation. Retina. 2003;23:417–20.PubMedCrossRef
9.
Sakimoto S, Gomi F, Sakaguchi H, Tano Y. Recurrent retinal angiomatous proliferation after surgical ablation. Am J Ophthalmol. 2005;139:917–8.PubMedCrossRef
10.
Shiragami C, Iida T, Nagayama D, Baba T, Shiraga F. Recurrence after surgical ablation for retinal angiomatous proliferation. Retina. 2007;27:198–203.PubMedCrossRef
11.
Boscia F, Furino C, Sborgia L, Reibaldi M, Sborgia C. Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol. 2004;138:1077–9.PubMedCrossRef
12.
Silva RM, Cachulo ML, Figueira J, de Abreu JR, Cunha-Vaz JG. Chorioretinal anastomosis and photodynamic therapy: a two-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2007;245:1131–9.PubMedCrossRef
13.
Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Investig Ophthalmol Vis Sci. 1996;37:1929–34.
14.
Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154–62.PubMedPubMedCentralCrossRef
15.
Oh H, Takagi H, Takagi C. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Investig Ophthalmol Vis Sci. 1999;40:1891–8.
16.
Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338–46.PubMedCrossRef
17.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, MARINA Study Group, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.PubMedCrossRef
18.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.PubMedCrossRef
19.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.CrossRef
20.
Hemeida TS, Keane PA, Dustin L, Sadda SR, Fawzi AA. Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br J Ophthalmol. 2010;94:701–5.PubMedPubMedCentralCrossRef
21.
Shin JY, Yu HG. Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients. Retina. 2014;34:2359–66.PubMedCrossRef
22.
Saito M, Shiragami C, Shiraga F, Nagayama D, Iida T. Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2008;146:935–41.PubMedCrossRef
23.
Saito M, Shiragami C, Shiraga F, Kano M, Iida T. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2010;149:472–81.PubMedCrossRef
24.
Saito M, Iida T, Kano M. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2012;153:504–14.PubMedCrossRef
25.
Saito M, Iida T, Kano M. Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol. 2013;57:211–20.PubMedCrossRef
26.
Sutter FK, Kurz-Levin MM, Fleischhauer J, Bösch MM, Barthelmes D, Helbig H. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Klin Monbl Augenheilkd. 2006;223:376–8.PubMedCrossRef
27.
Montero JA, Ruiz-Moreno JM, Sanabria MR, Fernandez-Munoz M. Efficacy of intravitreal and periocular triamcinolone associated with photodynamic therapy for treatment of retinal angiomatous proliferation. Br J Ophthalmol. 2009;93:166–70.PubMedCrossRef
28.
McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal angiomatous proliferation. Retina. 2011;31:1043–52.PubMedCrossRef
29.
Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP. Reticular pseudodrusen. A risk factor in age-related maculopathy. Retina. 1995;15:183–91.PubMedCrossRef
30.
Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y. Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology. 2010;117:303–12.PubMedCrossRef
31.
Ueda-Arakawa N, Ooto S, Nakata I, Yamashiro K, Tsujikawa A, Oishi A, et al. Prevalence and genomic association of reticular pseudodrusen in age-related macular degeneration. Am J Ophthalmol. 2013;155:260–9.PubMedCrossRef
32.
Finger RP, Wu Z, Luu CD, Kearney F, Ayton LN, Lucci LM, et al. Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization. Ophthalmology. 2014;121:1252–6.PubMedPubMedCentralCrossRef
33.
Cho HJ, Yoo SG, Kim HS, Kim JH, Kim CG, Lee TG, et al. Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol. 2015;159:285–92.PubMedCrossRef
34.
Tano Y, Ohji M, Ishibashi T, Shiraga F, Tokoro T, Yuzawa M, et al. Re-treatment guideline of ranibizumab (genetical recombination) in the maintenance phase. Nippon Ganka Gakkai Zasshi. 2009;113:1098–103 (in Japanese).PubMed
35.
Saito M, Iida T, Kano M. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Retina. 2012;32:1250–9.PubMed
36.
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report 1. Arch Ophthalmol. 1999;117:1329–45.CrossRef
37.
Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43–58.PubMedCrossRef
38.
Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151:281–91.PubMedPubMedCentral
39.
Gharbiya M, Allievi F, Recupero V, Martini D, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results. Retina. 2009;29:740–9.PubMedCrossRef
40.
Inoue M, Arakawa A, Yamane S, Kadonosono K. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography. Br J Ophthalmol. 2014;98:956–60.PubMedCrossRef
41.
Klein R, Klein BE, Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1993;100:406–14.PubMedCrossRef
42.
Sunness JS, Margalit E, Srikumaran D, Applegate CA, Tian Y, Perry D, et al. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology. 2007;114:271–7.PubMedPubMedCentralCrossRef
43.
Meyerle CB, Freund KB, Iturralde D, Spaide RF, Sorenson JA, Slakter JS, et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina. 2007;27:451–7.PubMedCrossRef
44.
Joeres S, Heussen FM, Treziak T, Bopp S, Joussen AM. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2007;245:1597–602.PubMedCrossRef
45.
Saito M, Iida T, Kano M, Itagaki K. Angiographic results of retinal–retinal anastomosis and retinal–choroidal anastomosis after treatments in eyes with retinal angiomatous proliferation. Clin Ophthalmol. 2012;6:1385–91.PubMedPubMedCentralCrossRef
46.
Engelbert M, Zweifel SA, Freund KB. “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29:1424–31.PubMedCrossRef
Metadata
Title
Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation
Authors
Masaaki Saito
Tomohiro Iida
Mariko Kano
Kanako Itagaki
Publication date
01-01-2016
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 1/2016
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-015-0417-x

Other articles of this Issue 1/2016

Japanese Journal of Ophthalmology 1/2016 Go to the issue

Clinical Investigation

Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection

Clinical Investigation

Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients

Laboratory Investigation

Neuroprotective effect of water-dispersible hesperetin in retinal ischemia reperfusion injury

Review

The microbiome, HLA, and the pathogenesis of uveitis

Clinical Investigation

Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring

Clinical Investigation

Stereoscopic perception of 3-D images by patients after surgery for esotropia